CYP26A1抗体;CYP26A1 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of CYP26A1 expression in HepG2 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

CYP26A1 is a member of the cytochrome P450 superfamily, specifically involved in the metabolism of retinoic acid (RA), a critical signaling molecule regulating cellular differentiation, embryonic development, and tissue homeostasis. This enzyme catalyzes the hydroxylation of RA into inactive metabolites, tightly controlling RA concentrations in tissues. Dysregulation of CYP26A1 is linked to developmental disorders, cancer progression, and skin diseases, making it a research focus in developmental biology and oncology.

CYP26A1 antibodies are immunological tools designed to detect and quantify the expression of this enzyme in various biological samples. They are typically produced using recombinant CYP26A1 proteins or synthetic peptides as immunogens, yielding polyclonal or monoclonal antibodies with high specificity. These antibodies enable researchers to study CYP26A1's tissue-specific expression patterns, subcellular localization, and regulatory mechanisms via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF).

In research, CYP26A1 antibodies help elucidate its role in RA signaling pathways, particularly in contexts like embryogenesis, neural patterning, and tumor resistance to RA-based therapies. For example, overexpression of CYP26A1 in certain cancers correlates with reduced RA efficacy, highlighting its potential as a therapeutic target. Validating antibody specificity through knockout controls or siRNA knockdown is essential to ensure accurate experimental outcomes. Overall, CYP26A1 antibodies are vital for advancing understanding of RA metabolism and its implications in health and disease.